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Abstract. In the present study we explored the effect of three
polymorphisms of the TS gene on overall and progression-
free survival of colorectal cancer (CRC) patients subjected
to 5FU chemotherapy. A 28 bp variable number of tandem
repeats (VNTR), a G/C single nucleotide polymorphism
(SNP), and a deletion of 6 bp at position 1494 were studied.
The possible combined effect of these DNA polymorphisms
on the clinical outcome of patients was also evaluated. A
retrospective study was carried out on paraffin-embedded
sections from 113 patients diagnosed of advanced CRC. TS
genotyping methods were polymerase chain reaction (PCR)
for VNTR and PCR, followed by restriction length fragment
polymorphism (PCR-RFLP) for SNP and ins/del 6 bp. To
study the combined effect of TS polymorphisms, four
categories were defined accordingly to the level of
expression attributed to SNP and ins/del 6 bp genotypes:
C&allele 6-, C&6+/6+, G&allele6- and G&6+/6+. VNTR
and ins/del 6 bp genotypes varied with tumour anatomical
site: 2R/2R genotype was rare in left-sided tumours (7.0%
vs. 26.3% of right-sided and 24.1% of rectal cancers;
P<0.01), where the variant allele 6- was very frequent
(69.0%). Instead, most patients with right-sided tumours
were wild-type homozygous 6+/6+ (63.9%) (P<0.01).
Heterozygous 6+/6- genotype was more frequent among
tumours classified as C (50.0%) and D (76.5%) Dukes stages
(P=0.05). None of the studied polymorphisms alone affected
overall or progression-free survival (PFS). C&6+/6+ and
G&6+/6+ combined genotypes were respectively associated
to the best and worst PFS (P=0.03 when compared with each
other), while combinations carrying the allele 6- determined
an intermediate evolution that might be indicative of a
variable response to chemotherapy. The rate of Dukes B
stage tumours was unexpectedly high (59.1%) among patients
with the unfavourable G&6+/6+ combination. In our study
the combination of high TS expression genotypes G&6+/6+
identifies a group of high risk within CRC patients treated
with 5FU.
Introduction
Thymidylate synthase (TS) is the therapeutic target for 5
fluorouracil (5FU) based chemotherapy, which is widely
used in a variety of tumours. This enzyme is essential for
DNA biosynthesis and repair, and it is directly involved in
cell proliferation. TS catalyzes the reductive methylation
of deoxyuridylate (dUMP) to thymidylate (dTMP), which
represents the only intracellular de novo source of dTMP
(1). The cytotoxic effect of 5FU and its derivatives is due to
their competition with dUMP. The consequence of TS
blocking is a depletion of dTMP levels resulting in thymine-
less death. High TS expression levels and catalytic activity
have been associated to poor prognosis and response rates
(2,3). The initial explanation was that elevated TS levels
overcome the inhibitory effect of chemotherapeutic drugs, but
latest experimental data have shown that high expression and
enzyme activity have oncogenic potential (4,5).
The gene encoding TS is located at 18p11.32. Three
polymorphisms affecting TS expression have been identified.
A variable number of tandem repeats (VNTR) of a 28 base
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pairs (bp) sequence, and a single nucleotide polymorphism
(SNP) are located within the 5' untranslated region (5'UTR).
The VNTR gives rise to alleles of two (2R) and three (3R)
repeats, although up to nine repetitions have been described
(6,7). Compared to the variant 2R allele, the wild-type 3R
has shown to enhance in vitro the translation of TS protein
because each one of the first two repeats harbours one USF
family E-box consensus element. The SNP, consists of a
G➝C substitution at the 12th nucleotide of the second repeat
of the 3R allele that abolishes its translation enhancer effect
because it eliminates the extra E-box site, thus preventing the
binding of USF complexes to it (8,9). Therefore, high TS
expression is due to the presence of the 3G allele, while 2R/
2R, 3C/3C, and 2R/3C genotypes lead to decreased TS levels
(8). A 6 bp deletion within the 3'UTR, at position 1494 has
also been disclosed (10). This ins/del polymorphism acts
on TS expression by affecting mRNA stability, so that the
deletion allele (del 6 bp, or 6-) mRNA displays a signi-
ficantly shorter half-life than that of the wild-type (ins 6 bp,
or 6+) (11,12).
A number of studies have been directed to elucidate if
differences in survival and/or response to 5FU-based chemo-
therapy of patients with cancer might have a genetic back-
ground. Data on the VNTR polymorphism are mixed (13).
These inconsistent results might be explained by the G/C
SNP but, although it has been proposed that patients carrying
the 3G allele have poorer outcome than low expressers
(14,15), the reported results are not consistent (16). Data on
TS 3'UTR polymorphism and survival are also heterogeneous
(17-19).
The aim of our study was to investigate whether TS
VNTR, SNP G/C and ins1494del 6 bp polymorphisms, either
alone or in combination, affect overall and/or progression-
free survival of patients with advanced colorectal cancer
(CRC) treated with 5FU.
Patients and methods
Subjects and treatment. The identification of TS gene
polymorphisms was carried out in a group of 113 patients
diagnosed of advanced colorectal carcinoma between 1993
and 2002 and subjected to surgical resection of their tumour.
Eighty-one of them had undergone adjuvant chemotherapy
treatment with 5FU. The chemotherapeutic agent was admi-
nistered via bolus regimen in all cases. The median of follow-
up was 59 (3-148) months.
Sample collection and genotyping. Samples consisted of
formalin fixed paraffin-embedded specimens of primary
tumours collected from the Archives of the Pathology
Department of the University Hospital of La Princesa (UAM,
Madrid, Spain). Data processing was carried out so that
patients' confidentiality was preserved.
DNA extraction. Genomic DNA was extracted from paraffin-
embedded tissue, as described earlier (20).
TS 5'UTR polymorphisms. VNTR and SNP polymorphisms
within the 5' UTR region of TS promoter were determined
respectively by specific PCR, and PCR-RFLP as described
earlier (14,20). As stated in previous reports based on
functional studies, subjects harbouring the 3G allele (i.e.,
2R/3G, 3G/3G and 3G/3C), were grouped as G patients
(5'UTR high expressors), and 2R/2R, 2R/3C, 3C/3C as C
patients (5'UTR low expressors) (9,14,21).
3' UTR polymorphism. The 6 bp deletion at position 1494 of
the 3' UTR region was determined by a PCR-RFLP method
based on that described by Ulrich et al (10). Briefly, 500 ng
of DNA were amplified in a final reaction volume of 50 μl
containing 15 pmol of each primer, 1 U of Biotools DNA
Polymerase (Biotools B&M Labs., S.A, Madrid, Spain), 1X
reaction buffer, 2.5 mM MgCl2, and 150 μM dNTPs. An
initial denaturation step of 94˚C for 5 min was followed by
40 cycles of denaturation (94˚C for 30 sec), annealing (59˚C
for 45 sec) and primer extension (72˚C for 45 sec), and a
final elongation step (72˚C for 5 min). The amplified
fragments (10-15 μl) were digested overnight at 37 ˚C with
DraI restriction endonuclease, and the fragments were
electrophoresed on 4% high resolution agarose (Conda
Laboratories, Madrid, Spain). Wild-type (6+) and variant (6-)
alleles were ascertained respectively by the presence of two
fragments of 70 and 88 bp, or one fragment of 152 bp. The
heterozygous genotype displayed all of these bands, together
with the 158 bp one, corresponding to residual undigested
wild-type product described elsewhere (10).
PCR was carried out in a GeneAmp PCR System 2700
(Applied Biosystems, Foster City, CA, USA). All PCR
primers were provided by Metabion International AG.
(Martinsried, Germany). The remaining PCR reagents were
supplied by Biotools B&M Labs, and restriction endonu-
cleases were supplied by MP Biomedicals (Irvine, CA.
USA).
Definition of TS5' and 3'UTR combined genotypes. Combined
TS 5'UTR and 3'UTR genotypes were grouped following
the classification proposed by Kawakami et al (21), which
defines four categories basing on the level of TS expression
ascribed to TS5' and 3'UTR genotypes. Namely, these groups
are C&allele 6- (5'UTRLow/3'UTRLow); C&6+/6+
(5'UTRLow/3'UTRHigh); G&allele 6- (5'UTRHigh/
3'UTRLow), and G&6+/6+ (5'UTRHigh/3'UTRHigh). High
and low TS5'UTR expressors have been defined above;
TS3'UTRLow expressers include all carriers of the variant
6- allele (i.e. homozygous 6-/6- and heterozygous 6+/6-), and
TS3'UTRHigh expressors are homozygous 6+/6+ subjects.
Statistical analysis. The endpoint of the study was overall
and progression-free survival, calculated from the primary
surgery to the date of last follow-up or death (overall survival)
or to the first evidence of disease progression (progression-
free survival). Demographic and clinical variables were
compared across genotype, using Fisher's exact test or the
Pearson ¯2 test for categorical variables and the one-way
analysis of variance for continuous and normally distributed
variables or the Kruskall-Wallis test for non-normal variables.
Normality was checked by the Kolmogorov-Smirnov test. To
verify the agreement of the observed genotype frequencies
with those expected according to the Hardy-Weinberg equi-
librium model (22), the likelihood-ratio test G was used.
FERNÁNDEZ-CONTRERAS et al:  COMBINED TS 5' AND 3'UTR GENE POLYMORPHISMS IN ADVANCED CRC220
219-229  2/12/2008  01:02 ÌÌ  ™ÂÏ›‰·220
Survival (OS) and progression-free survival (PFS) curves
were plotted using the Kaplan and Meier method (23) and
compared with the log-rank, Breslow and Tarone-Ware
tests. The estimation of overall and progression-free survival
was performed only in patients treated with 5FU with an
overall survival (OS) of 6 months or longer. Median follow-
up time was computed for all patients alive at the time of
analysis. Statistical significance was assumed for P<0.05
two-tail tests. All analyses were performed using the SPSS
software, version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
A total of 113 patients were enrolled in this study between
1993 and 2002. The median follow-up for all of them was 59
months (range 3-148). Patients characteristics are shown in
Table I. Median age was 66 years (range 39-90); 43.4% were
male; 71.7% received adjuvant chemotherapy.
TS polymorphisms. Genotype distributions of VNTR, SNP
G/C, ins/del 6 bp polymorphisms, and their combinations are
summarized in Table II. VNTR, SNP G/C and ins/del 6 bp
genotyping were assessable in 113, 111 and 110 patients
respectively. The frequencies of VNTR and ins/del 6 bp geno-
types were in agreement with those expected accordingly to
Hardy-Weinberg equilibrium model (22).
TS genotypes and clinicopathological variables. Table III
shows the genotype frequencies of TS polymorphisms
relating to Dukes stage, tumour location, number of dead
and number of relapsed patients. The latter two variables
refer to patients receiving adjuvant therapy with 5FU, with
the exception of those dead of causes not related to cancer.
The same correlations with regard to TS5' and 3'UTR
combined genotypes are summarized in Table IV. No
differences related to age and gender were observed (data
not shown). Due to their small number, the three cases with
tumours located in transverse colon are not discussed. Two
of these patients were homozygous 3R/3R, and one was
2R/2R; all of them were SNP C (5'UTRLow expressors) and
homozygous 6+/6+ (combined genotype C&6+/6+).
Dukes stage. The frequency of 6+/6- genotype in patients
with tumours classified as C and D stages was 50% and
76.5% respectively, vs. 35.3% of B2 (P=0.05). No association
between this variable and TS 5'UTR VNTR and SNP poly-
morphisms or combined genotypes was found.
Tumour location. Homozygous 2R/2R genotype was signi-
ficantly less frequent in left-sided tumours (7% vs. 26.3% of
right-sided and 24.1% of rectal ones; P<0.01). Left location
was also associated to a higher proportion of 3G carriers
(65% vs. 35% of C), although without reaching statistical
signification (P=0.06). Heterozygous 6+/6- and variant
homozygous genotypes were also more frequent in this site,
compared to right-sided tumours (59.5% vs. 30.6% and 9.5%
vs. 5.4%). In contrast, wild-type homozygous 6+/6+ was
strongly associated to right-sided location (63.9%) (P=0.04).
The link between ins/del 6 bp genotype and anatomical
location of the tumour was more marked when all 6- allele
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Table I. Baseline characteristics of the patients.
–––––––––––––––––––––––––––––––––––––––––––––––––
N (%)
–––––––––––––––––––––––––––––––––––––––––––––––––
Age (years, median range) 66.0 (39-90)
Median OS (months) 59.0 (3-148)
Median PFS (months) 34.5 (2-147)
Gender
Male 49 (43.4)
Female 64 (56.6)
Dukes stage
B2 52 (46.0)
C 44 (39.0)
D 17 (15.0)
Tumour location
Right 38 (33.6)
Transverse 3 (2.7)
Left 43 (38.1)
Rectum 29 (25.7)
Mortality
Alive 51 (45.1)
Dead of CRC 23 (20.4)
Dead of unrelated cause 5 (4.4)
Lost 34 (30.1)
–––––––––––––––––––––––––––––––––––––––––––––––––
OS, overall survival; PFS, progression-free survival.
–––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Genotype frequencies of TS polymorphisms alone
and in combination.
–––––––––––––––––––––––––––––––––––––––––––––––––
N (%)
–––––––––––––––––––––––––––––––––––––––––––––––––
VNTR (N=113)
3R/3R 29 (25.7)
2R/3R 62 (54.9)
2R/2R 22 (19.5)
SNP (N=111)
G 60 (53.6)
C 52 (46.4)
Ins/del 6 bp (N=110)
6+/6+ 51 (46.4)
6+/6- 52 (47.3)
6-/6- 7 (6.4)
Combined genotype (N=110)
C&allele 6- 21 (19.1)
C&6+/6+ 29 (26.4)
G&allele 6- 38 (34.5)
G&6+/6+ 22 (20.0)
–––––––––––––––––––––––––––––––––––––––––––––––––
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carriers were grouped together. These patients showed 69%
of left-sided and 58.6% of rectal tumours (P<0.01). G&allele
6- combined genotype was more frequent in left colon (50%)
and rectum (41.4%) than in right colon (13.9%) (P<0.01).
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Table III. Correlation between TS polymorphisms and clinicopathological variables.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
VNTR SNP ins/del 6 bp
–––––––––––––––––––––––––––––––––– –––––––––––––––––––––––– –––––––––––––––––––––––––––––––––
3R/3R 2R/3R 2R/2R P-value High Low P-value 6+/6+ 6+/6- 6-/6- P-value
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Dukes stage
B2 14 (26.9) 25 (48.1) 13 (25.0) 0.6 27 (51.9) 25 (48.1) 0.6 28 (54.9) 19 (35.3) 5 (9.8) 0.05
C 10 (22.7) 28 (63.6) 6 (13.6) 22 (51.2) 21 (48.8) 19 (45.2) 21 (50.0) 2 (4.8)
D 5 (29.4) 9 (52.9) 3 (17.6) 11 (64.7) 6 (35.3) 4 (23.5) 13 (76.5) 0
Tumour
location
Right 7 (18.4) 21 (55.3) 10 (26.3) 16 (43.2) 21 (56.8) 23 (63.9) 11 (36.0) 2 (5.6)
Transverse 1 (33.3) 0 2 (66.7) <0.01 0 3 (100) 0.06 3 (100) 0 0 0.04
Left 18 (41.9) 22 (51.2) 3 (7.0) 28 (65.1) 15 (34.9) 13 (31.0) 25 (59.5) 4 (9.5)
Rectum 3 (10.3) 19 (65.5) 7 (24.1) 16 (55.2) 13 (44.8) 2 (41.4) 16 (55.2) 1 (3.4)
Mortalitya
Dead 1 (7.7) 11 (84.6) 1 (7.7) 0.07 7 (53.8) 6 (46.2) 0.4 5 (38.5) 8 (61.5) 0 0.2
Alive 12 (29.3) 20 (48.8) 9 (22.0) 19 (46.3) 22 (53.7) 18 (43.9) 17 (41.5) 6 (14.6)
Relapsea
Yes 6 (17.6) 23 (67.6) 5 (14.7) 0.2 17 (51.5) 16 (48.5) 0.4 14 (42.4) 17 (51.5) 2 (6.1) 0.6
No 9 (30.0) 14 (46.7) 7 (23.3) 14 (46.7) 16 (53.3) 13 (43.3) 13 (43.3) 4 (13.3)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aPatients treated with adjuvant chemotherapy and overall survival of 6 months or longer. Subjects dead of unrelated causes were excluded.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Table IV. Correlation between TS 5'/3'UTR combined genotype and clinicopathological variables.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
TS 5'/3'UTR combined genotype
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
C&allele 6- C&6+/6+ G&allele 6- G&6+/6+ P-value
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Dukes stage
B2 9 (17.6) 15 (29.4) 14 (27.5) 13 (25.5) 0.3
C 7 (16.7) 13 (31.0) 16 (38.1) 6 (14.3)
D 5 (29.4) 1 (5.9) 8 (47.1) 3 (17.6)
Tumour location
Right 8 (22.2) 12 (33.3) 5 (13.9) 11 (30.6)
Transverse 0 3 (100) 0 0 <0.01
Left 8 (19.0) 6 (14.3) 21 (50.0) 7 (16.7)
Rectum 5 (17.2) 8 (27.6) 12 (41.4) 4 (13.8)
Mortalitya
Alive 4 (30.8) 2 (15.4) 4 (30.8) 3 (23.1) 0.4
Dead 8 (19.5) 14 (34.1) 15 (36.6) 4 (9.8)
Relapsea
Yes 8 (24.2) 8 (24.2) 11 (33.3) 6 (18.2) 0.4
No 5 (17.2) 11 (37.9) 12 (37.9) 2 (6.9)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aPatients treated with adjuvant chemotherapy and overall survival of 6 months or longer. Subjects dead of unrelated causes were excluded.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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No other associations between tumour location and the
remaining genotype combinations were found.
Mortality and relapsing. A trend towards higher mortality
was found for 2R/3R genotype, which was present in 11/13
deceased patients (84.9%) (P=0.07). No other associations
between TS genotype and number of deaths and relapses
were found.
TS genotypes and survival. Median OS value was not reached
in the overall group of patients included in the Kaplan-Meier
analysis. Median PFS was 98 months.
TS5'UTR polymorphisms and survival. The survival analysis
did not reveal any influence of VNTR genotype on PFS
(log-rank P=0.4; data not shown). However, a trend to worse
OS was found for 2R/3R patients (Fig. 1; P=0.08). In view of
this result, the distribution of TS combined genotypes within
this group was determined and compared to 3R/3R patients.
The combinations carrying the 6- allele (i.e., C&allele 6-
and G&-allele 6-) were present in 22/31 (71%) patients
with 2R/3R genotype vs. 6/13 (46.2%) of 3R/3R, although
differences were not significant (P=0.3, data not shown).
SNP G/C had no effect on OS and PFS (P=0.5 and 0.4
respectively; data not shown).
TS3'UTR polymorphism and survival. Survival plots did
not show any association between ins/del 6 bp genotype
alone and overall or progression-free survival (P=0.3 and
P=0.5; data not shown).
TS combined genotypes. Median PFS values were 36.0 months
(95%CI: 0-108.5) and 22.0 months (95%CI: 6.8-37.2),
respectively for patients with C&allele 6- and G&6+/6+
combined genotypes. Subjects with the remaining TS
5'/3'UTR combinations did not reach median OS or PFS
values. Fig. 2 shows the survival plots. When the four groups
were taken together, no association between TS combined
genotype and overall or progression-free survival was
observed (P=0.3 and P=0.2 respectively).
Separate analyses comparing groups by pairs were also
performed (plots not shown). Log-rank P-values for OS and
PFS are shown in Table V. Groups C&6+/6+ and G&6+/6+
displayed respectively the best and worst evolution. Group
G&6+/6+ showed significantly shorter PFS than group
C&6+/6+ (P=0.03). A similar trend was observed for OS
(P=0.09). The remaining analyses did not reveal differences.
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Figure 1. VNTR and overall survival (log-rank P=0.08.)
Figure 2. Overall and progression-free survival plots of TS combined genotypes. OS, overall survival (log-rank P=0.3); PFS, progression-free survival
(log-rank P=0.2).
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Allele 6- and survival. Kaplan-Meier plots revealed that
patients with combined genotypes C&allele 6- and G&allele
6- seemed to integrate a group of intermediate evolution
between C&6+/6+ and G&6+/6+. As the variant allele 6-
showed an association with differential clinicopathological
characteristics (i.e., left tumour location, and C and D stage),
we based on the premise that tumours carrying the allele 6-
might display a special behaviour, and classified our patients
in three groups: C&6+/6+, G&6+/6+, and 6- carriers. Fig. 3
shows the survival analyses. Significant differences were not
observed when considering all the three groups, but survival
plots confirmed that 6- carriers represented an intermediate
situation between C&6+/6+ and G&6+/6+ combinations.
Low expression genotypes and survival. Finally, we
evaluated the effect of the presence of at least one genotype
of low TS expression on OS and PFS, compared with the
combination of TS5'/3'UTR high expression G&6+/6+.
Again, this genotype showed a trend to shorter PFS (P=0.08,
Fig. 4); there were no significant differences with respect
to OS. The G&6+/6+ group included in the Kaplan-Meier
analysis included eight patients whose OS and PFS periods
are enumerated in Table VI. Six of them (75%) relapsed
and their PFS period gradually increased to a maximum
of 34 months; however, the PFS of the two patients that
did not relapse reached 115 months. This striking variation
substantially increased the overall progression-free period
of this group, and accounts for the lack of statistical
differences with the remaining patients.
Characteristics of patients harbouring the combined
genotypes of favourable (C&6+/6+), intermediate (G or
C&Allele 6-) and unfavourable (G&6+/6+) evolution. The
clinicopathological characteristics of patients carrying the
allele 6- and the combinations C&6+/6+ and G&6+/6+
respectively associated to intermediate, favourable, and
unfavourable outcome, were compared. The data are
summarized in Table VII. There were no differences with
respect to age and gender (data not shown).
The rate of left-sided tumours was higher among allele
6- carriers (49.2% vs. 22% right-sided and 28.8% rectal),
while right colon and rectal cancers were more frequent in
patients with C&6+/6+ and G&6+/6+ combined genotypes
(41.4 and 50% respectively) (P<0.01). Number of deceased
and relapsed patients did not differ significantly among the
three groups. Concerning the Dukes stage, the proportion of
B2, C and D tumours was comparable in allele 6- carriers
(39%, B2; 39% C, and 22% D); meanwhile, the rate of B2
tumours reached 51.7 and 59.1% in patients harbouring
respectively the genotype combinations of best (C&6+/6+)
and worst (G&6+/6+) evolution.
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Table V. Analysis by pairs of the four TS combined geno-
types.
–––––––––––––––––––––––––––––––––––––––––––––––––
P-value (log-rank)
–––––––––––––––––
OS PFS
–––––––––––––––––––––––––––––––––––––––––––––––––
C&allele 6- vs. C&6+/6+ 0.2 0.2
C&allele 6- vs. G&allele 6- 0.4 0.4
C&allele 6- vs. G&6+/6+ 0.7 0.5
C&6+/6+ vs. G&allele 6- 0.4 0.5
C&6+/6+ vs. G&6+/6+ 0.09 0.03
G&allele 6- vs. G&6+/6+ 0.3 0.1
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 3. Overall and progression-free survival plots of combination genotypes C&6+/6+, G&6+/6+ and allele 6- carriers. Median overall survival was not
reached in any of the established groups (log-rank P=0.2). Median progression-free survival was not reached by C&6+/6+ patients; it was 98 months
for 6- allele carriers and 22 months (CI95%= 6.8-37.2) for group G&6+/6+ (log-rank P=0.1). OS, overall survival; PFS, progression-free survival.
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Discussion
DNA polymorphisms disclosed within TS gene have shown
to influence protein expression at different levels. TS5'UTR
G/C SNP acts on mRNA expression and translational
efficiency (8,9,14), while TS3'UTR ins/del 6 bp involves
mRNA stability (11,12). The importance of TS as therapeutic
target for 5FU has favoured a number of investigations
directed to elucidate the possible role of these polymorphisms
as genetic markers of response to chemotherapy and/or
survival (13). The variant 2R, 3C and 6- alleles have been
associated to low TS expression, which has been linked to
better clinical outcome of treated patients because low TS
levels are expected to be better targeted by its inhibitors. In
contrast, high TS levels have shown to induce transformation
and tumour progression, which strongly supports an oncogenic
role of this enzyme (4,5). However, in the clinical practice,
the relationship between TS genotype and survival and/or
response to 5FU based chemotherapy remains unclear (16).
Genotype frequencies of TS polymorphisms. In our study, the
frequencies of 2R/2R, 3R/3R and 2R/3R genotypes were
19.7, 24.8 and 55.6% respectively, which is consistent with
those published in Caucasians (7,25,26). VNTR is subjected
to race variability: the reported rates of 2R/2R patients
are around 20% in White, Black or South-Western Asian
populations (3,15,18,27,28), but rarely reaches 10% in Japan,
China and Korea (24,29,30), were the 3R allele is predominant
(7). The same is true for the proportion of TS5'UTR high
and low expressors defined by the SNP G/C accordingly to
Kawakami and Watanabe (14). Such grouping is based on
the effect of the G/C substitution within the second repeat
of the 3R allele, that is the disruption of an extra E-box site.
As a result, the levels of expression of 3C/3C and 2R/2R
genotypes are comparable, while the presence of the wild-type
3G allele promotes high TS expression (14). The
classification of patients as high an low expressors (in our
study G and C) basing on the SNP G/C has greatly simplified
the correlation of this polymorphism with clinical parameters
(9,14,17). TS5'UTR high expressors represent >60% of
Chinese and Japanese (9,14) patients, while its presence in
Caucasians is about 50% (3,15,17,27,28). The percentages of
G and C patients found by us were 52.8 and 47.2%, which
is close to those reported in France (17), but slightly diverge
from other studies carried out in our country, were C
genotype was the most frequent (15,19).
Ethnic variations have also been reported for the
frequencies of ins/del 6 bp genotypes. The proportion of
6+/6+ wild-type homozygous patients is 40-50% among
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Figure 4. Overall and progression-free survival plots of carriers of at least one TS low expression genotype vs. G&6+/6+ patients. OS, Overall survival (log-
rank P=0.2); PFS, progression-free survival (log-rank P=0.08)
Table VI. Values of overall and progression-free survival
of TS5'/3'UTRHigh expressers (G&6+/6+) included in the
Kaplan-Meier analysis.
–––––––––––––––––––––––––––––––––––––––––––––––––
Patient OS (months) Dead PFS (months) Relapsed
–––––––––––––––––––––––––––––––––––––––––––––––––
1 19 Lost 5 Yes
2 20 Yes 12 Yes
3 40 Yes 19 Yes
4 76 Yes 22 Yes
5 79 No 30 Yes
6 111 No 34 Yes
7 115 No 115 No
8 115 No 115 No
–––––––––––––––––––––––––––––––––––––––––––––––––
OS, overall survival; PFS, progression-free survival.
–––––––––––––––––––––––––––––––––––––––––––––––––
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Caucasians, were 6-/6- are rare (around 10%). These
frequencies are inverted in Asian CCR patients (26,31-33).
These variations are a consequence of an imperfect linkage
disequilibrium reported for 3G and 6- alleles, which are the
most common among Asian subjects (21).
Genotype frequencies of TS combined genotypes. The
frequencies of patients with C&allele 6-, C&6+/6+, G&allele
6-, and G&6+/6+ genotype combinations defined as a
function of TS expression by Kawakami et al (21) were 19.1,
26.4, 34.5 and 20.0% respectively (these groups are termed
as A, B, C and D in the referred study). Our figures are close
to those reported by these authors in patients with gastric
carcinoma (28% C&allele 6-, 21% C&6+/6+, 40% G&allele
6-, and 11% G&6+/6+), except for the slight inversion
between the frequencies of groups C&allele6- and C&6+/6+,
and our higher rate of patients with G&6+/6+ genotype. To
our knowledge, the only study considering combinations of
TS5' and 3'UTR high and low expressor genotypes in CCR
patients, where TS5'UTR expression is based on the SNP
G/C is that recently reported by Lurje et al (33). However,
their data are not completely comparable to ours because
heterozygous 3G carriers (2R/3G and 3G/3C), widely stated
as TS5'UTR high expressors (14-16,34) are differentiated
here as ‘intermediate’ expressors. In this investigation, only
13 out of 178 patients (7.3%) harboured the G&6+/6+
combined genotype (TS5'UTRHigh or Intermediate/
TS3'UTRHigh), which is significantly less than our 20.0%
(P<0.01). The inclusion in Lurje's series of 25 Asian patients,
22 out of whom (88%) were carriers of the 6- allele (i.e.
TS3'UTRLow), consequently reduces the frequency of
G&6+/6+ genotype and probably explains these differences.
TS polymorphisms and clinicopathological variables. Dukes
stage. Ins/del 6 bp was the only polymorphism showing an
association with tumour stage, heterozygous 6+/6- being
more frequent in advanced stages (50% C and 76.5% D). A
trend between allele 6- and advanced stage, borderline to
statistical signification (P=0.055) has been observed in our
country by Dotor et al (19). Conversely, Curtin et al have
reported a link between the presence of variant 2R and/or 6-
alleles to reduced risk of having an advanced stage tumour
(31).
Tumour location. We detected strong associations between
TS genotype and anatomical site of the tumour. Differences
were more obvious between left and right locations. Left-
sided carcinomas were characterized by a remarkably low
percentage (7%) of two repeats homozygous (2R/2R),
compared to right-sided (26.3%) and rectal ones (24.1%),
and a high proportion of 3R/3R (41.9 vs. 18.4% right colon
and 10.3% rectum). Also, carriers of allele 6- and G patients
represented respectively 69 and 65.1% of cases in this site,
probably reflecting the linkage disequilibrium between 6-
and 3G alleles. In contrast, right-sided tumours were linked
to TS3'UTR wild-type homozygous 6+/6+genotype (69%),
but were not related to TS5'UTR SNP or VNTR polymor-
phisms. Regarding rectal tumours, the genotype distribution
associated to ins/del 6 bp and SNP G/C polymorphisms,
tended to follow the pattern observed for left colon, although
differences were not so striking (the percentages of alleles
6- and 3G carriers were 58.1 and 55.2% respectively). As
a consequence, G&allele 6- combined genotype was the more
frequent in left colon and rectum (50 and 41.4% respectively,
vs. 13.9% of right colon). No remarkable differences were
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Table VII. Clinicopathological characteristics of patients with C&6+/6+, G or C&Allele 6- and G&6+/6+ combinations.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
C&6+/6+ G or C&Allele 6- G&6+/6+ P-value
N=29 N=59 N=22
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Dukes stage
B2 15/29 (51.7) 23/59 (39.0) 13/22 (59.1) 0.1
C 13/29 (44.8) 23/59 (39.0) 6/22 (27.3)
D 1/29 (3.4) 13/59 (22.0) 3/22 (13.6)
Tumour location
Right 12/29 (41.4) 13/59 (22.0) 11/22 (50.0) <0.01
Transverse 3/29 (10.3) 0 0
Left 6/29 (20.7) 29/59 (49.2) 7/22 (31.8)
Rectum 8/29 (27.6) 17/59 (28.8) 4/22 (18.2)
Mortalitya
Yes 2/16 (12.5) 8/31 (25.8) 3/7 (42.9) 0.3
No 14/16 (87.5) 23/31 (74.2) 4/7 (57.1)
Relapsea
Yes 8/19 (42.1) 19/36 (52.8) 6/8 (75.0) 0.3
No 11/19 (57.9) 17/36 (47.2) 2/8 (25.0)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aPatients treated with adjuvant chemotherapy and overall survival of 6 months or longer. Subjects dead of unrelated causes were excluded.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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seen for VNTR, except for the slightly elevated rate of
2R/3R. One may speculate that these variations of genotype
distribution with regard to the anatomical location might
indicate that colorrectal carcinoma comprises tumours with
differential characteristics in terms of origin or carcinogenic
pathways. In Spain, Dotor et al (19) found no link between
these two variables, but their results are not com-parable to
ours because they grouped together left-sided and rectal
tumours. A poorer prognosis has been reported for rectal
carcinomas (35,36). In contrast, while some authors do not
establish clear differences in the behaviour of left and right-
sided tumours (32) a favourable prognosis for right colon
carcinomas has been reported by others (36). Even so, the
only objective fact is that, by now, we do not know the
biological meaning of this association between TS genotype
and tumour location.
TS polymorphisms and survival. TS 5' UTR polymorphisms.
VNTR. Table III shows that 11/13 (84.6%) deceased patients
treated with 5FU, with an OS of at least six months were
heterozygous 2R/3R (P=0.07). The Kaplan-Meier analysis
also revealed a trend to shorter OS for these patients (P=0.08),
while 3R/3R and 2R/2R displayed similar behaviour. The
reported data on the prognostic or predictive value of VNTR
are imprecise and conflicting (8,13,18,37,38). Although
better survival and/or longer time to progression have been
widely linked to 2R/2R genotype, variable outcomes have
been reported for 3R/3R and 2R/3R patients. Heterozygous
2R/3R genotype has been proposed as a favourable marker
in some studies (30,38). In contrast, other authors have
found a strong association with elevated enzyme activity,
which is a proven adverse marker (3,39-41), 3R/3R
predicting better response to chemotherapy (3). Combination
TS 5' and 3'UTR genotypes were not taken into account in
those studies. When we determined their frequencies among
heterozygous 2R/3R patients, and compared them to those of
homozygous 3R/3R, we found that combinations carrying the
6- allele (i.e., C&allele 6- and G&allele 6-) were present in
71% of 2R/3R patients, vs. 46.2% of 3R/3R. This might be
important if we consider that, in our study, the presence of
the 6- allele was linked to advanced tumour stage. Other
factors that should be taken into consideration in further
investigations are the variations of TS gene copy number due
to loss of heterozygosis (LOH) or gene amplification. By
targeted disruption of one allele, Brody et al (42) have
shown that 3R-loss genotype leads to reduced TS protein
expression and increased sensitivity to 5FU. LOH is a
frequent event in carcinogenesis, and an elevated proportion
of 3R-loss among presumed 3R/3R patients might explain
the unexpected favourable outcome and the decreased
enzyme activity reported in some studies for this genotype
(3), and the poorer prognosis of 2R/3R (3,43). On the other
hand, TS gene amplification has shown to increase TS
expression and resistance to 5FU (44,45). Variations in TS
copy number due to these mechanisms are undetectable by
direct PCR methods, extensively used to screen TS genotype.
SNP G/C. In a previous investigation, we reported a link
between SNP G and shorter PFS, that was borderline to
statistical signification (log-rank P=0.06; Breslow P=0.04,
and Tarone Ware P=0.05) (20). However, when follow-up
was increased and clinical data were updated for the present
study, such association was not confirmed, and this poly-
morphism alone did not affect either overall or progression-
free survival. Despite the clear in vitro enhancer effect of
3G allele on TS expression, our data add more variability
to the reported results about the prognostic and predictive
value of this marker in the clinical practice (16,34).
TS 3' UTR polymorphisms. The Kaplan-Meier analysis did
not reveal any effect of TS3' UTR genotype alone on survival,
which is consistent with some studies (17,31). Instead, an
association of the variant 6- allele with a reduced risk of
death, together with an adverse prognosis for 6+/6+ genotype
has been reported by others (19).
TS combined genotypes. Although without statistical signi-
fication, the survival analysis of the four combined geno-
types pointed to a poorer outcome for patients harbouring
the TS5'/3'UTR high expression combination G&6+/6+.
Separate analyses comparing groups by pairs revealed
marked differences in terms of PFS between C&6+/6+ and
G&6+/6+ groups that were linked respectively to the best and
worst prognosis. A similar trend was found regarding OS,
although log-rank P-value did not reached the threshold of
statistical significance. When we evaluated the effect of at
least one genotype of low TS expression, G&6+/6+ patients
also tended to display shorter PFS. In our study, this group
was integrated by 8 patients, 6 of whom had relapsed with
a PFS range of 5-34 months. However, the PFS period of
the two remaining patients that did not relapse was 115
months. This dramatic difference and the small size of this
group account for the lack of statistical significance in the
survival analyses, and we believe that our findings support
that G&6+/6+ combined genotype is a marker of poor
prognosis in CCR patients treated with 5FU. Kawakami
et al, who defined this classification for the first time, also
reported that this combination, that was present in 10 subjects
in their study, was associated to the poorest prognosis in
gastric cancer (21). We failed to find other studies following
this classification based on SNP and ins/del polymorphism.
Recently, Lurje et al (33) have proposed another sorting were
2R/3G, and 3C/3G patients, included as high TS expressors
in most studies, are considered as ‘intermediate’ expressors,
giving rise to two additional categories. Their investigation
was carried out in stages II and III CCR patients subjected
to adjuvant chemotherapy with 5FU. The differentiation
of TS5'UTR intermediate expressors makes unsuitable
to compare their data of survival with ours. Moreover
G&allele 6- and G&6+/6+ combined genotypes (in their
study ‘TS5'UTR high/TS3'UTR high or low’) were grouped
together for the Kaplan-Meier analysis. Even so, the authors
also concluded that the 3G/6+ haplotype is a marker of
poor prognosis and is associated to the greatest risk of
recurrence.
In contrast to us, both Kawakami (21) and Lurje (33)
observed that the best prognosis corresponded to TS5'/
3'UTRLow expressor (group C&allele 6-) patients with
gastric cancer and colorectal carcinoma. In our study,
combination genotypes harbouring the 6- allele seemed to be
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associated to an intermediate evolution. Based on the
survival plots and on the previous observations that tumours
carrying the deletion allele displayed differential clinico-
pathological features (left location, advanced stage), we
regrouped the patients as C&6+/6+, G&6+/6+ and 6- carriers
(G or C&allele 6-). The Kaplan-Meier test confirmed this
‘intermediate’ behaviour of 6- carriers, suggesting that the
deletion modulates the effect of SNP on response to
chemotherapy. The ‘low TS expression' associated to 6-
allele is due to an impaired mRNA stability. This is caused
by the decay-promoting RNA binding protein (RBP) AUF-1,
which displays preferential affinity for the variant 6- mRNA.
A number of RBPs join to both 6- and 6+ mRNAs, but only
AUF-1 binding to the variant transcript is significantly
stronger than the union to the wild-type messenger. The
consequence is a decrease in 6- mRNA levels that represents
4- to 6-fold that of the wild-type ones (12). It is likely that
this phenomenon affects the grade of expression determined
by G/C SNP. This is specially important, given that TS is the
only eukaryotic protein whose expression is controlled by
binding to its own mRNA (46), because messenger stability
might particularly affect this unique post-translational
regulatory mechanism. In our study, C&6+/6+ and G&6+/6+,
or, in other words, C and G patients with ‘stable’ 6+ mRNA,
display a substantially different behaviour in terms of PFS,
being respectively associated to the best and worst prognosis,
as expected if considering the data of functional studies on the
SNP G/C. In contrast, the survival plots of C and G patients
with ‘unstable’ 6- mRNA are very close and integrate a
group of intermediate evolution between C&6+/6+ and
G&6+/6+. This finding might be indicative of the suggested
inter-ference of the variant 6- transcript on the response to
5FU based chemotherapy.
Table VII shows the characteristics of patients with
combined genotypes C&6+/6+ (good prognosis), G&6+/6+
(bad prognosis) and G or C&Allele 6- (intermediate pro-
gnosis). There are no appraisable differences among them,
with the exception of the higher frequency of left-sided
tumours among 6- carriers, already discussed. However,
surprisingly, the rate of B2 stage tumours reached 59.1% of
G&6+/6+. As Dukes stage B is accepted as an independent
marker of better prognosis, the proportion of B2 tumours
was unexpectedly elevated in a group of patients carrying a
genotypic combination that resulted associated to the worst
outcome.
In summary, our data support that G&6+/6+ (TS5'/3'UTR
high expression) combined genotype identifies a group
of poor prognosis among advanced CCR patients treated
with 5FU based adjuvant chemotherapy, while the presence
of the 6- allele is linked to variable response to treatment.
Moreover, if confirmed in further studies, the biological
meaning of the association of certain TS genotypes with
particular tumour locations should be investigated.
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